Clinical trials: Tace
Carcinoma, Hepatocellular
Safety and Efficacy of "Immuncell-LC" in TACE Therapy
To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma
- Trial name
- NCT02856815
- Testing
- Immuncell-LC
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma
Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System
The aim of this study is to establish a selection criteria of hepatectomy for patients with multiple hepatocellular carcinomas based on the NDR Scoring System
- Trial name
- NCT02525952
- Testing
- Hepatectomy, TACE
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Liver Neoplasm, Colorectal Cancer Metastatic
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
A total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group…
- Trial name
- CLEAR-DEBIRI (NCT06555003)
- Testing
- Drug-Eluting Embolic Bead, Chemotherapy drug
- Where
- Iran
- Volunteers
- 116 people
- Sponsor
- Tehran University of Medical Sciences
Hepatocellular Carcinoma
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
- Trial name
- NCT05925413
- Testing
- Cadonilimab+TACE
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
The purpose of the study is to observe the effect of Lenvatinib Combined With TACE in preventing the recurrence in high-risk patients with hepatocellular carcinoma.
- Trial name
- NCT03838796
- Testing
- lenvatinib, TACE
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma
The purpose of this observational study is to evaluate properties of lipiodol-idarubicin emulsion mixed with the best regimen obtained in vitro study, including stability, viscosity，visibility under X-ray and deposition, in order…
- Trial name
- NCT05631613
- Testing
- cTACE(conventional transarterial chemoembolization)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT02220088
- Testing
- TAI of FOLFOX, Sorafenib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Hepatocellular Carcinoma (HCC)
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with…
- Trial name
- NCT07075562
- Testing
- Bevacizumab Arterial Perfusion plus TACE, Conventional Therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Hospital of Hebei Medical University
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Colorectal Neoplasms Malignant
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
- Trial name
- TACE-Ax-HCQ (NCT04873895)
- Testing
- Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients…
- Trial name
- NCT04174781
- Testing
- Sintilimab, DEB-TACE
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University
Nodular Goiter
TACE Treats Nodular Goiter
transarterial bleomycin chemoembolization represents a novel minimally invasive therapeutic approach for the management of giant nodular goiter.
- Trial name
- NCT07258199
- Testing
- TACE
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Hepato Cellular Carcinoma
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
- Trial name
- CineDoxo (NCT03706157)
- Testing
- Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Carcinoma, Hepatocellular
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.
- Trial name
- NCT04560751
- Testing
- Lenvatinib, TACE
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
- Conditions
- Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma, Digestive System Neoplasms
- Trial name
- NCT06794073
- Testing
- Multimodal Thermal Therapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Zhongshan Hospital